Filing Flows › Lemaitre Vascular (LMAT) › Q1 2025
Lemaitre Vascular (LMAT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Lemaitre Vascular (LMAT) reported revenue of $59.9M for the first quarter 2025 (Q1 2025), +12% from a year earlier and +7% from the quarter before. Operating margin was 21.1%, net earnings $11.0M (18.4% of revenue).
Lemaitre Vascular, Q1 2025: revenue $59.9M (+12% year over year), operating margin 21.1%, net earnings $11.0M, operating cash flow $9.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59.9M | +7% | +12% |
| Gross profit | $41.4M | +7% | +13% |
| Operating profit | $12.6M | -2% | +6% |
| Net earnings | $11.0M | -2% | +11% |
| Operating cash flow | $9.0M | -40% | +78% |
| Free cash flow | $7.7M | -42% | +107% |
What changed
Revenue was $59.9M in Q1 2025, up 12% year over year and up 7% from the previous quarter.
Gross margin was 69.2%, up 0.6 points from a year earlier. Operating profit was $12.6M, a 21.1% margin (down 1.1 points year over year). Of the extra revenue versus a year earlier, 12% reached operating profit, below the 22% margin then. Operating expenses grew 16% against revenue growth of 12%. The fastest-growing cost line was Sales & marketing (+22%). Net earnings were $11.0M, up 11% year over year. The effective tax rate was 22.7%.
Operating cash flow was $9.0M (up 78% year over year), 82% of net earnings. Non-cash charges added back $2.6M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $6.6M. Capital expenditures of $1.4M left free cash flow of $7.7M.
Questions
What was Lemaitre Vascular's revenue in the first quarter 2025?
Lemaitre Vascular (LMAT) reported revenue of $59.9M for the first quarter 2025 (Q1 2025), +12% from a year earlier and +7% from the quarter before.
Was Lemaitre Vascular profitable in the first quarter 2025?
Operating profit was $12.6M (21.1% of revenue) and net earnings $11.0M.
Source: Lemaitre Vascular 10-Q on SEC EDGAR.